GlobeNewswire Press

  1. Mustang Bio Announces $9.28M Grant To Fund Phase 1 Trial Of CAR T Therapy MB-103 In HER2-Positive Breast Cancer With Brain Metastases 8/13/2019

    Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope has received a $9.28 million grant from the California Institute for Regenerative Medicine (CIRM) to fund an ongoing Phase 1 clinical trial of MB-103 (HER2‐specific CAR T cells) for the treatment of HER2-positive breast cancer with brain metastases.

  2. Passage Bio Announces Launch Of Natural History Study To Evaluate Patients With GM1 Gangliosidosis 8/13/2019

    Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the launch of a Natural History Study to evaluate patients with Type 1 and Type 2 GM1 gangliosidosis, a rare autosomal recessive genetic disorder that progressively destroys nerve cells in the brain and spinal cord.

  3. Athenex Announces Oral Paclitaxel And Encequidar Had A Significantly Higher Response Rate Over IV Paclitaxel In A Phase III Pivotal Study In Metastatic Breast Cancer 8/7/2019

    Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced topline data showing that oral paclitaxel and encequidar (Oral Paclitaxel) met the primary efficacy endpoint with statistically significant improvement over IV paclitaxel in a Phase III pivotal study in metastatic breast cancer.

  4. ADC Therapeutics And SOPHiA GENETICS Partner For Biomarker Discovery In Pivotal Phase II Clinical Trial 8/6/2019

    ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven Medicine, today announced they have entered into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine).

  5. Eloxx Pharmaceuticals Announces Initiation Of Phase 2 Clinical Trial For ELX-02 In Cystinosis 8/5/2019

     Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it has initiated a Phase 2 clinical trial (Study 003) for ELX-02 in cystinosis in Canada.

  6. Alkahest Announces Positive Top-line Data From Phase 2 Study In Mild To Moderate Alzheimer's Disease 8/5/2019

    Alkahest, Inc., a clinical-stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced top-line data from its phase 2 clinical trial of its candidate GRF6019 in mild-to-moderate Alzheimer’s disease dementia (AD).

  7. SELLAS Announces Completion Of Enrollment In Randomized Phase 2 VADIS Trial Of Nelipepimut-S (NPS) In Women With Ductal Carcinoma In Situ (DCIS) Of The Breast 8/5/2019

    SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced completion of enrollment in a Phase 2 randomized investigator-sponsored trial (IST) of nelipepimut-S (NPS) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in women with ductal carcinoma in situ (DCIS) of the breast who are HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+, or 3+ levels, and are pre- or post-menopausal.

  8. Radius Health Initiates Phase 3 wearABLe Study Of Abaloparatide-Patch In Postmenopausal Osteoporosis Patients At High Risk For Fracture 8/5/2019

    Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the randomization of the first patient in the Phase 3 wearABLe clinical trial studying the safety and efficacy of abaloparatide-transdermal patch (abaloparatide-patch) in the treatment of postmenopausal patients with osteoporosis at high risk for fracture.

  9. AZTherapies Completes Enrollment In COGNITE Pivotal Phase 3 Trial Of ALZT-OP1 For The Treatment Of Early Alzheimer's Disease 8/1/2019

    AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced that it has completed target enrollment in its COGNITE Phase 3 clinical trial, evaluating the safety and efficacy of ALZT-OP1 for the treatment of early Alzheimer’s disease.

  10. Arcturus Therapeutics Receives Up To $15M Commitment From The Cystic Fibrosis Foundation To Create mRNA Therapies To Treat Cystic Fibrosis Patients 8/1/2019

    Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that the Cystic Fibrosis Foundation (CF Foundation), has increased its commitment to $15 million in conjunction with an amended agreement to advance LUNAR-CF, a novel messenger RNA (mRNA) therapeutic formulated with Arcturus’ LUNAR® delivery technology.